Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Organogenesis Holdings Inc.NASDAQ: ORGO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $20.21M (cash outflow) rose 883.1% year over year, ahead of the -226.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 320.3% from the prior quarter. Over 3 fiscal years it compounded at +99.1% a year.
Context
- Financing cash flow amounted to 3.1% of revenue in FY2025, down 2.6 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +883.1% holds above the trailing-twelve-month pace of -226.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (17.36M) USD
- Year-over-year change
- -162.8%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (17.36M) | -162.8% |
| FY2024 | 2024-12-31 | 27.64M | +602.0% |
| FY2023 | 2023-12-31 | (5.51M) | -150.3% |
| FY2022 | 2022-12-31 | (2.2M) | -112.3% |
| FY2021 | 2021-12-31 | (1.04M) | — |
Financing Cash Flow vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -226.0% is the 9th highest of 11, against a peer median of -9.6%.
- Financing cash flow amounts to 6.9% of revenue for ORGO, versus a peer median of 11.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $231M USD | -286.4% | +47.2% | 26.9% | |
| LTM Mar 2026 | $147.6M USD | -36.1% | — | 21.8% | |
| LTM Mar 2026 | $133.79M USD | +14802.1% | +19.6% | — | |
| LTM Mar 2026 | $91.49M USD | +63.4% | +1307.1% | — | |
| LTM Mar 2026 | $59.9M USD | +615.4% | +3.5% | 14.3% | |
| LTM Mar 2026 | CA$50.85M CAD | -20.7% | +9.2% | 5.4% | |
| LTM Mar 2026 | $44.12M USD | +1.5% | -1.8% | 47.0% | |
| LTM Mar 2026 | $35.52M USD | -226.0% | +99.1% | 6.9% | |
| LTM Mar 2026 | $26.59M USD | +21872.7% | — | 8.8% | |
| LTM Feb 2026 | $5.1M USD | -1089.9% | — | 1.6% | |
| LTM Mar 2026 | $143.84K USD | -100.0% | — | 0.2% | |
| Peer median (excluding ORGO) | — | -9.6% | +14.4% | 11.6% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 94.9M | 15.53M | 4.95M | 861K | 37.03M |
| Depreciation & Amortization | 16.68M | 10.73M | 23.45M | 17.03M | 26.94M |
| Deferred Income Tax | (31.98M) | 1.98M | 2.01M | (10.72M) | 9.5M |
| Stock-Based Compensation | 3.86M | 6.55M | 9M | 10.58M | 13.3M |
| Change in Working Capital | (39.29M) | (34.08M) | (18.07M) | (48.89M) | (132.38M) |
| Accounts Receivables | (30.23M) | (8.77M) | 5.54M | (31.8M) | (115.8M) |
| Inventory | (9.3M) | (9.41M) | 6.58M | (6.2M) | (17.92M) |
| Accounts Payables | 3.85M | 3.26M | (108K) | (2.37M) | (528K) |
| Other Working Capital | (3.6M) | (19.16M) | (30.08M) | (8.51M) | 1.87M |
| Other Non-Cash Items | 17.8M | 24.15M | 9.59M | 45.35M | 35.3M |
| Operating Cash Flow | 61.98M | 24.86M | 30.92M | 14.21M | (10.31M) |
| Capital Expenditures | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Debt Repayment | (2.01M) | (3.01M) | (5.17M) | (67.64M) | (1.17M) |
| Common Stock Issued | 2.2M | 0 | 0 | 0 | 157K |
| Common Stock Repurchased | 0 | 0 | 0 | (25.48M) | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.8M) | 0 |
| Other Financing Activities | (1.22M) | 814K | (332K) | 1.87M | (16.35M) |
| Financing Cash Flow | (1.04M) | (2.2M) | (5.51M) | 27.64M | (17.36M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 29.72M | (11.24M) | 1.05M | 31.81M | (41.82M) |
| Free Cash Flow | 30.76M | (9.04M) | 6.55M | 4.18M | (24.46M) |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.